{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:34:17Z","timestamp":1792985657398,"version":"4.5.0"},"reference-count":238,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.diabet.2026.101725","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:18:55Z","timestamp":1770340735000},"page":"101725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-6714","authenticated-orcid":false,"given":"Benjamin","family":"Bouillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Boulestreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"B\u00e9liard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil","family":"Charri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.diabet.2026.101725_bib0001","first-page":"1670\u201181","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: college of cardiology\/American Heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0003","doi-asserted-by":"crossref","first-page":"111\u201188","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2026.101725_bib0004","first-page":"646","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease:college of cardiology\/American heart association task force on clinical practice guidelines","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.diabet.2026.101725_bib0005","doi-asserted-by":"crossref","first-page":"3227\u2011337","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.diabet.2026.101725_bib0006","doi-asserted-by":"crossref","first-page":"1637\u201146","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A test in Context:ipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0007","doi-asserted-by":"crossref","first-page":"61\u20116","DOI":"10.1016\/j.clinbiochem.2017.11.007","article-title":"Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital","volume":"52","author":"Cartier","year":"2018","journal-title":"Clin Biochem"},{"key":"10.1016\/j.diabet.2026.101725_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.diabet.2026.101725_bib0009","doi-asserted-by":"crossref","first-page":"4043\u2011140","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Heart J"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0010","article-title":"Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus:paper of the French Society of Cardiology and the French-speaking Society of Diabetology","volume":"47","author":"Valensi","year":"2021","journal-title":"Metab"},{"key":"10.1016\/j.diabet.2026.101725_bib0011","first-page":"ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0012","first-page":"182\u20119","article-title":"Validation of systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in the EPIC-Norfolk prospective population cohort","volume":"31","author":"van Trier","year":"2024","journal-title":"J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0013","doi-asserted-by":"crossref","first-page":"247\u20119","DOI":"10.1177\/2047487320916589","article-title":"Imaging subclinical atherosclerosis in cardiovascular risk stratification","volume":"28","author":"Kozakova","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0014","first-page":"177\u201184","article-title":"Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis:a systematic review","volume":"98","author":"Peters","year":"2012","journal-title":"Br Card Soc"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0015","doi-asserted-by":"crossref","first-page":"503\u20119","DOI":"10.1001\/jamacardio.2024.5644","article-title":"Coronary artery calcium testing\u2014too early, late, often","volume":"10","author":"Zheutlin","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0016","doi-asserted-by":"crossref","first-page":"1181\u20119","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a calcium score equate to secondary prevention?: Insights from the multinational CONFIRM registry","volume":"16","author":"Budoff","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0017","doi-asserted-by":"crossref","first-page":"2414\u201124","DOI":"10.1016\/j.jcmg.2021.06.011","article-title":"The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia","volume":"14","author":"Gallo","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0018","doi-asserted-by":"crossref","first-page":"1332\u201140","DOI":"10.1001\/jamacardio.2017.4191","article-title":"Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis","volume":"2","author":"Malik","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0019","doi-asserted-by":"crossref","first-page":"67\u201173","DOI":"10.1016\/j.pcad.2023.03.002","article-title":"Coronary artery calcium, hepatic steatosis, and atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus: results from the Dallas heart study","volume":"78","author":"Khawaja","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.diabet.2026.101725_bib0020","first-page":"924\u201133","article-title":"Coronary CT angiography and 5-year risk of myocardial infarction","volume":"379","author":"Adamson","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.diabet.2026.101725_bib0021","doi-asserted-by":"crossref","first-page":"796\u2011803","DOI":"10.1001\/jama.2012.9630","article-title":"Common carotid intima-media thickness measurements in cardiovascular risk prediction:meta-analysis","volume":"308","author":"Den Ruijter","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2026.101725_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102147","article-title":"Usefulness of carotid ultrasound screening in primary cardiovascular prevention: a systematic review","author":"Sebastian","year":"2024","journal-title":"Probl Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005179","article-title":"Comparison of carotid plaque score and coronary artery calcium score for predicting cardiovascular disease events: the multi-ethnic study of atherosclerosis","author":"Gepner","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0024","doi-asserted-by":"crossref","first-page":"129\u201136","DOI":"10.1016\/j.ejvs.2019.07.039","article-title":"Three dimensional carotid and femoral ultrasound is not superior to two dimensional ultrasound as a predictor of coronary atherosclerosis among men with intermediate cardiovascular Risk","volume":"59","author":"Jarauta","year":"2020","journal-title":"Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0025","doi-asserted-by":"crossref","first-page":"24\u201147","DOI":"10.1161\/ATVBAHA.123.320138","article-title":"Assessment of subclinical atherosclerosis in asymptomatic people in vivo: measurements suitable for biomarker and mendelian randomization studies","volume":"44","author":"Garg","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.diabet.2026.101725_bib0026","first-page":"1191\u2011204","article-title":"Cardiac calcification as a marker of subclinical atherosclerosis and predictor of cardiovascular events: review of the evidence","volume":"26","author":"Faggiano","year":"2019","journal-title":"J Prev Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0027","unstructured":"Lecoffre C. LDL cholesterol in adults in metropolitan France: average concentration, awareness, and treatment in 2015, changes since 2006. Bull Epid\u00e9miologique Hebd. 37."},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0028","doi-asserted-by":"crossref","first-page":"1146\u201155","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins:a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0029","doi-asserted-by":"crossref","first-page":"46\u201163","DOI":"10.3945\/ajcn.2009.27661","article-title":"Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review","volume":"91","author":"Hunter","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.diabet.2026.101725_bib0030","doi-asserted-by":"crossref","first-page":"373\u201180","DOI":"10.1007\/s11883-023-01109-y","article-title":"Eggs and cardiovascular disease risk: an update of recent evidence","volume":"25","author":"Carter","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"10.1016\/j.diabet.2026.101725_bib0031","first-page":"1001\u201111","article-title":"Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis","volume":"17","author":"Zomer","year":"2016","journal-title":"Rev Off J Int Assoc Study Obes"},{"key":"10.1016\/j.diabet.2026.101725_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0033","doi-asserted-by":"crossref","first-page":"1579\u201193","DOI":"10.1038\/s41430-019-0504-z","article-title":"Phytosterol compositions of enriched products influence their cholesterol-lowering efficacy:a meta-analysis of randomized controlled trials","volume":"73","author":"Ying","year":"2019","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0034","doi-asserted-by":"crossref","first-page":"507\u201119","DOI":"10.1002\/ptr.8052","article-title":"The effect of phytosterol supplementation on lipid profile: a critical umbrella review of interventional meta-analyses","volume":"38","author":"Wang","year":"2024","journal-title":"Phytother Res PTR"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41467-021-27706-6","article-title":"Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis","volume":"13","author":"Scholz","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabet.2026.101725_bib0036","unstructured":"Phytosterol-enriched foods: no overall benefit in preventing cardiovascular disease demonstrated | Anses - French Agency for Food, Environmental and Occupational Health & Safety [Internet]. [cited Sept. 25, 2025]. Available at: https:\/\/www.anses.fr\/fr\/content\/aliments-enrichis-en-phytosterols-un-benefice-global-sur-la-prevention-des-maladies."},{"issue":"19","key":"10.1016\/j.diabet.2026.101725_bib0038","doi-asserted-by":"crossref","first-page":"1483\u201192","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0039","article-title":"Exercise for overweight or obesity","author":"Shaw","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0040","doi-asserted-by":"crossref","first-page":"117\u201124","DOI":"10.1016\/j.ahj.2012.04.014","article-title":"Exercise effects on lipids in persons with varying dietary patterns\u2014does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through defined exercise I","volume":"164","author":"Huffman","year":"2012","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0041","doi-asserted-by":"crossref","first-page":"9\u201119","DOI":"10.1016\/j.ypmed.2008.10.010","article-title":"Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"48","author":"Kelley","year":"2009","journal-title":"Prev Med"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0042","doi-asserted-by":"crossref","first-page":"261\u20118","DOI":"10.1136\/bjsports-2023-107221","article-title":"Do the associations of daily steps with mortality and incident cardiovascular disease differ by sedentary time levels? A device-based cohort study","volume":"58","author":"Ahmadi","year":"2024","journal-title":"Br J Sports Med"},{"issue":"7224","key":"10.1016\/j.diabet.2026.101725_bib0043","doi-asserted-by":"crossref","first-page":"1523\u20118","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and hemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2026.101725_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d671","article-title":"Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis","author":"Ronksley","year":"2011","journal-title":"BMJ"},{"issue":"10152","key":"10.1016\/j.diabet.2026.101725_bib0045","first-page":"987\u20118","article-title":"No level of alcohol consumption improves health","volume":"392","author":"Burton","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"6676","key":"10.1016\/j.diabet.2026.101725_bib0046","doi-asserted-by":"crossref","first-page":"784\u20118","DOI":"10.1136\/bmj.298.6676.784","article-title":"Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data","volume":"298","author":"Craig","year":"1989","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0047","doi-asserted-by":"crossref","first-page":"344\u201153","DOI":"10.1053\/euhj.1998.1194","article-title":"Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: artery study","volume":"20","author":"Price","year":"1999","journal-title":"Heart J"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0048","article-title":"Smoking and diabetes interplay: comprehensive review and joint statement","volume":"48","author":"Durlach","year":"2022","journal-title":"Metab"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0049","doi-asserted-by":"crossref","first-page":"553\u201161","DOI":"10.1016\/j.je.2016.12.017","article-title":"Smoking and the risk of type 2 diabetes in Japan: a systematic review and meta-analysis","volume":"27","author":"Akter","year":"2017","journal-title":"J Epidemiol"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0050","doi-asserted-by":"crossref","first-page":"1030\u201145","DOI":"10.1016\/j.jacc.2018.06.036","article-title":"Prevention and treatment of tobacco use: JACC health promotion series","volume":"72","author":"Kalkhoran","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0051","unstructured":"Haute Autorit\u00e9 de sant\u00e9. 2014."},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0052","doi-asserted-by":"crossref","first-page":"139\u201151","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0053","doi-asserted-by":"crossref","first-page":"485\u201194","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0054","doi-asserted-by":"crossref","first-page":"212\u20117","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0055","doi-asserted-by":"crossref","first-page":"257\u201164","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"10","key":"10.1016\/j.diabet.2026.101725_bib0056","first-page":"1057\u201166","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Metab Cardiovasc Dis NMCD"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0057","doi-asserted-by":"crossref","first-page":"1546\u201153","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database","volume":"51","author":"Barter","year":"2010","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0058","doi-asserted-by":"crossref","first-page":"69\u201176","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"issue":"9841","key":"10.1016\/j.diabet.2026.101725_bib0059","first-page":"581\u201190","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet Lond Engl."},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0060","first-page":"403\u201114","article-title":"B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013thestudy","volume":"19","author":"Bruckert","year":"2005","journal-title":"Drugs Ther"},{"issue":"10059","key":"10.1016\/j.diabet.2026.101725_bib0061","first-page":"2532\u201161","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.diabet.2026.101725_bib0062","doi-asserted-by":"crossref","first-page":"g3743","DOI":"10.1136\/bmj.g3743","article-title":"Non-cardiovascular effects associated with statins","volume":"349","author":"Desai","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0063","first-page":"464\u201174","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug?Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0064","doi-asserted-by":"crossref","first-page":"390\u20119","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins:a study-level network meta-analysis of 246,955 participants from 135 randomized-, trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0065","doi-asserted-by":"crossref","first-page":"2788\u201197","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"10355","key":"10.1016\/j.diabet.2026.101725_bib0066","first-page":"832\u201145","article-title":"Effect of statin therapy on muscle symptoms:individual participant data meta-analysis of large-scale, randomized, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"10088","key":"10.1016\/j.diabet.2026.101725_bib0067","first-page":"2473\u201181","article-title":"Adverse events associated with unblinded, but not with blinded, therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Arm (ASCOT-LLA): a randomized double-blind placebo-controlled trial and its non-randomized non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"22","key":"10.1016\/j.diabet.2026.101725_bib0068","doi-asserted-by":"crossref","first-page":"2182\u20114","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101725_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomized, placebo-controlled n-of-1 trials","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2026.101725_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"9601","key":"10.1016\/j.diabet.2026.101725_bib0071","first-page":"1781\u201190","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0072","first-page":"146\u201151","article-title":"Statin-associated rhabdomyolysis: is there a dose-response relationship?","volume":"27","author":"Holbrook","year":"2011","journal-title":"Can J Cardiol"},{"issue":"27","key":"10.1016\/j.diabet.2026.101725_bib0073","doi-asserted-by":"crossref","first-page":"2526\u201139","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy:the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Heart J"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0074","doi-asserted-by":"crossref","first-page":"148\u201152","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030714","article-title":"Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials","author":"B\u00e9trisey","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0076","article-title":"LDL-cholesterol lowering agents (statins and PCSK9 inhibitors) and the risk of intracerebral hemorrhage: A network meta-analysis","volume":"34","author":"Li","year":"2025","journal-title":"J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0077","doi-asserted-by":"crossref","first-page":"881\u201192","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"30","key":"10.1016\/j.diabet.2026.101725_bib0078","doi-asserted-by":"crossref","first-page":"4808\u201117","DOI":"10.1200\/JCO.2006.06.3560","article-title":"Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials","volume":"24","author":"Bonovas","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"21","key":"10.1016\/j.diabet.2026.101725_bib0079","doi-asserted-by":"crossref","first-page":"2554\u201168","DOI":"10.1016\/j.jacc.2019.09.041","article-title":"Effects of statins on memory, cognition, and brain volume in the elderly","volume":"74","author":"Samaras","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0080","doi-asserted-by":"crossref","first-page":"3145\u201156","DOI":"10.1016\/j.jacc.2021.04.075","article-title":"Effect of statin therapy on cognitive decline and incident dementia in older adults","volume":"77","author":"Zhou","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0081","first-page":"415\u201127","article-title":"Ezetimibe therapy:mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0082","first-page":"568\u201180","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0083","doi-asserted-by":"crossref","first-page":"251\u201161","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response:a pooled analysis of over 21,000 subjects from 27 trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.diabet.2026.101725_bib0084","doi-asserted-by":"crossref","first-page":"1606\u201113","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0085","doi-asserted-by":"crossref","first-page":"2387\u201197","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0086","doi-asserted-by":"crossref","first-page":"258\u201165","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.diabet.2026.101725_bib0087","doi-asserted-by":"crossref","first-page":"1713\u201122","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabet.2026.101725_bib0088","doi-asserted-by":"crossref","first-page":"2097\u2011107","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0089","doi-asserted-by":"crossref","first-page":"563\u201179","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0090","doi-asserted-by":"crossref","first-page":"800\u20117","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.diabet.2026.101725_bib0091","first-page":"1075\u201183","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci Lond Engl 1979"},{"issue":"39","key":"10.1016\/j.diabet.2026.101725_bib0092","doi-asserted-by":"crossref","first-page":"2981\u20119","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Heart J"},{"issue":"15","key":"10.1016\/j.diabet.2026.101725_bib0093","doi-asserted-by":"crossref","first-page":"1109\u201119","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0094","first-page":"995\u20111004","article-title":"PCSK9 inhibition and risk of diabetes: should we worry?","volume":"24","author":"Carugo","year":"2022","journal-title":"Atheroscler Rep"},{"key":"10.1016\/j.diabet.2026.101725_bib0095","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.diabet.2026.101725_bib0096","doi-asserted-by":"crossref","first-page":"1022\u201132","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabet.2026.101725_bib0097","doi-asserted-by":"crossref","first-page":"1353\u201164","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.diabet.2026.101725_bib0098","doi-asserted-by":"crossref","first-page":"1033\u201142","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabet.2026.101725_bib0099","first-page":"1833\u201149","article-title":"Current treatments for the management of homozygous familial hypercholesterolaemia:a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"J Prev Cardiol"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0100","doi-asserted-by":"crossref","first-page":"880\u20119","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of pediatric patients with homozygous familial hypercholesterolemia (APH-19): results from the efficacy phase of an open-label, multicenter, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0101","first-page":"413\u201123","article-title":"Italian Working Group on Lomitapide. Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Int. Off J Int Assoc Study Liver."},{"issue":"8","key":"10.1016\/j.diabet.2026.101725_bib0102","doi-asserted-by":"crossref","first-page":"711\u201120","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0103","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv. Nov."},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0104","doi-asserted-by":"crossref","first-page":"412\u201124","DOI":"10.1592\/phco.27.3.412","article-title":"Fibrates: what have we learned in the past 40 years?","volume":"27","author":"Backes","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0105","first-page":"314\u201145","article-title":"Niacin and fibrates in atherogenic dyslipidemia:armacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Ther"},{"key":"10.1016\/j.diabet.2026.101725_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.diabet.2026.101725_bib0107","doi-asserted-by":"crossref","first-page":"2061\u201171","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.diabet.2026.101725_bib0108","doi-asserted-by":"crossref","first-page":"804\u201111","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0109","doi-asserted-by":"crossref","first-page":"410\u20118","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Affairs high-density lipoprotein cholesterol intervention trial study group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med."},{"issue":"20","key":"10.1016\/j.diabet.2026.101725_bib0110","doi-asserted-by":"crossref","first-page":"1237\u201145","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabet.2026.101725_bib0111","first-page":"694","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.diabet.2026.101725_bib0112","first-page":"1563\u201174","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.diabet.2026.101725_bib0113","doi-asserted-by":"crossref","first-page":"1923\u201134","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0114","first-page":"651\u201164","article-title":"EPA\u2019s pleiotropic mechanisms of action: a narrative review","volume":"133","author":"Nelson","year":"2021","journal-title":"Med"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0115","doi-asserted-by":"crossref","first-page":"682\u201190","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (the Multi-center, placebo-controlled,, double-blind, 12-week study with an open-label extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol."},{"issue":"7","key":"10.1016\/j.diabet.2026.101725_bib0116","doi-asserted-by":"crossref","first-page":"984\u201192","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0117","doi-asserted-by":"crossref","first-page":"94\u2011106","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia:EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0118","doi-asserted-by":"crossref","first-page":"321\u201130","DOI":"10.1016\/j.jacl.2017.10.012","article-title":"Omega-3 carboxylic acids in patients with severe hypertriglyceridemia:randomized, placebo-controlled trial","volume":"12","author":"Stroes","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0119","doi-asserted-by":"crossref","first-page":"11\u201122","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.diabet.2026.101725_bib0120","first-page":"1540\u201150","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0121","first-page":"23\u201132","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabet.2026.101725_bib0122","doi-asserted-by":"crossref","first-page":"2268\u201180","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.diabet.2026.101725_bib0123","doi-asserted-by":"crossref","first-page":"2200\u20116","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0124","first-page":"22\u201131","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0125","doi-asserted-by":"crossref","first-page":"32\u201141","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0126","doi-asserted-by":"crossref","first-page":"531\u201142","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1016\/j.diabet.2026.101725_bib0127","doi-asserted-by":"crossref","first-page":"1781\u201192","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0128","doi-asserted-by":"crossref","first-page":"127\u201137","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0129","doi-asserted-by":"crossref","first-page":"846\u201157","DOI":"10.1016\/j.jhep.2024.01.030","article-title":"Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population","volume":"80","author":"Wargny","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.diabet.2026.101725_bib0130","first-page":"2334\u201143","article-title":"Time-course atherogenic blood lipid response to statin discontinuation in dyslipidemic adults","volume":"34","author":"Alvarez-Jimenez","year":"2024","journal-title":"Metab Cardiovasc Dis NMCD"},{"issue":"6807","key":"10.1016\/j.diabet.2026.101725_bib0131","first-page":"893\u20116","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the simon broome register group","volume":"303","year":"1991","journal-title":"BMJ"},{"issue":"45","key":"10.1016\/j.diabet.2026.101725_bib0132","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2026.101725_bib0133","doi-asserted-by":"crossref","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","author":"Marduel","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.diabet.2026.101725_bib0134","doi-asserted-by":"crossref","first-page":"334\u201140","DOI":"10.1016\/j.atherosclerosis.2018.08.010","article-title":"High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia:Hypercholesterolemia Registry","volume":"277","author":"B\u00e9liard","year":"2018","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0135","doi-asserted-by":"crossref","first-page":"2277\u201191","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0136","first-page":"325\u201133","article-title":"The complex role of triglycerides in cardiovascular disease","volume":"2","author":"Abdel-Maksoud","year":"2002","journal-title":"Vasc Med"},{"issue":"9726","key":"10.1016\/j.diabet.2026.101725_bib0137","first-page":"1634\u20119","article-title":"Triglyceride-mediated pathways and coronary disease:analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0138","doi-asserted-by":"crossref","first-page":"124\u201130","DOI":"10.1016\/j.jacl.2022.10.008","article-title":"The relationship of alcohol consumption and HDL metabolism in the multiethnic dallas heart study","volume":"17","author":"Badia","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"47","key":"10.1016\/j.diabet.2026.101725_bib0139","doi-asserted-by":"crossref","first-page":"4791\u2011806","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: tabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0140","doi-asserted-by":"crossref","first-page":"352\u201162","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2013diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2026.101725_bib0141","doi-asserted-by":"crossref","first-page":"265\u201172","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS):recommendations and proposal of an \"FCS score","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0142","first-page":"547\u201163","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: from epidemiology, and Biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Res"},{"issue":"Suppl C","key":"10.1016\/j.diabet.2026.101725_bib0143","first-page":"C2\u201112","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"Ferrari","year":"2016","journal-title":"Eur Heart J Suppl J Eur Soc Cardiol"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0144","doi-asserted-by":"crossref","first-page":"e1332\u201142","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-Year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11883-014-0437-x","article-title":"Congenital lipodystrophies and dyslipidemias","volume":"16","author":"Prieur","year":"2014","journal-title":"Atheroscler Rep"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0146","doi-asserted-by":"crossref","first-page":"2799\u2011807","DOI":"10.1194\/jlr.M600312-JLR200","article-title":"Heritability and genetic loci of fatty liver in familial combined hyperlipidemia","volume":"47","author":"Brouwers","year":"2006","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0147","doi-asserted-by":"crossref","first-page":"274\u201182","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.diabet.2026.101725_bib0148","doi-asserted-by":"crossref","first-page":"655\u201166","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2026.101725_bib0149","doi-asserted-by":"crossref","first-page":"35\u201143","DOI":"10.1016\/j.atherosclerosis.2021.11.032","article-title":"Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia","volume":"340","author":"Trinder","year":"2022","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.diabet.2026.101725_bib0150","doi-asserted-by":"crossref","first-page":"1933\u201149","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia. Questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabet.2026.101725_bib0151","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMicm1713658","article-title":"Xanthoma striatum palmare","author":"Koehler","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0152","doi-asserted-by":"crossref","first-page":"184\u201190","DOI":"10.1210\/clinem\/dgac503","article-title":"Dysbetalipoproteinemia is associated with increased risk of coronary and peripheral vascular disease","volume":"108","author":"Paquette","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101725_bib0153","article-title":"Evaluation of biochemical algorithms to screen dysbetalipoproteinemia in \u03b52\u03b52 and rare APOE variants carriers","author":"Michenaud","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0154","doi-asserted-by":"crossref","first-page":"2198\u2011206","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","journal-title":"Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0155","doi-asserted-by":"crossref","first-page":"1191\u2011201","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Obes Metab"},{"key":"10.1016\/j.diabet.2026.101725_bib0156","doi-asserted-by":"crossref","first-page":"1\u201112","DOI":"10.1016\/S1567-5688(15)30001-5","article-title":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia:from an expert consensus meeting on the role of fenofibrate-statin combination therapy","volume":"19","author":"Aguiar","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"9","key":"10.1016\/j.diabet.2026.101725_bib0157","doi-asserted-by":"crossref","first-page":"3939\u201185","DOI":"10.1210\/jc.2019-01338","article-title":"Primary prevention of ASCVD and T2DM in patients at metabolic risk: an endocrine society* clinical practice guideline","volume":"104","author":"Rosenzweig","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101725_bib0158","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2022.101196","article-title":"Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: meta-analysis of randomized controlled trials","volume":"88","author":"Yang","year":"2022","journal-title":"Prog Lipid Res"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0159","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0160","first-page":"442\u20119","article-title":"Cardiovascular disease in type 1 diabetes:review of epidemiological data and underlying mechanisms","volume":"46","author":"Verg\u00e8s","year":"2020","journal-title":"Metab"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0161","first-page":"886\u201199","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"ay"},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0162","doi-asserted-by":"crossref","first-page":"422\u201134","DOI":"10.1016\/j.tem.2020.01.015","article-title":"Dyslipidemia in type 1 diabetes: AMaskedDanger","volume":"31","author":"Verg\u00e8s","year":"2020","journal-title":"Trends Endocrinol Metab TEM"},{"issue":"9607","key":"10.1016\/j.diabet.2026.101725_bib0163","first-page":"117\u201125","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"10.1016\/j.diabet.2026.101725_bib0164","doi-asserted-by":"crossref","first-page":"2109\u201122","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.diabet.2026.101725_bib0165","first-page":"684\u20116","article-title":"Mechanisms of diabetic dyslipidemia:atherogenesis","volume":"10","author":"Arca","year":"2012","journal-title":"Vasc Pharmacol"},{"issue":"11","key":"10.1016\/j.diabet.2026.101725_bib0166","doi-asserted-by":"crossref","first-page":"1040\u20118","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes:a randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0167","doi-asserted-by":"crossref","first-page":"1027\u201137","DOI":"10.2337\/dc20-1843","article-title":"Liraglutide increases the catabolism of apolipoprotein b100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin\/\/type 9 expression","volume":"44","author":"Verg\u00e8s","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101725_bib0168","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus:meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"9889","key":"10.1016\/j.diabet.2026.101725_bib0169","first-page":"339\u201152","article-title":"Chronic kidney disease and cardiovascular risk: idemiology, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"9731","key":"10.1016\/j.diabet.2026.101725_bib0170","first-page":"2073\u201181","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0171","doi-asserted-by":"crossref","first-page":"577\u201185","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0172","doi-asserted-by":"crossref","first-page":"238\u201148","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.diabet.2026.101725_bib0173","doi-asserted-by":"crossref","first-page":"1395\u2011407","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"9784","key":"10.1016\/j.diabet.2026.101725_bib0174","doi-asserted-by":"crossref","first-page":"2181\u201192","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (of Heart and Renal Protection):a randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.diabet.2026.101725_bib0175","first-page":"829\u201139","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens:a meta-analysis of individual participant data from 28 randomized trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.diabet.2026.101725_bib0176","doi-asserted-by":"crossref","first-page":"2961\u201170","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"10.1016\/j.diabet.2026.101725_bib0177","doi-asserted-by":"crossref","first-page":"4114\u201123","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0178","doi-asserted-by":"crossref","first-page":"29\u201141","DOI":"10.1161\/CIRCULATIONAHA.112.000500","article-title":"Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010","volume":"128","author":"Egan","year":"2013","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0179","first-page":"2439\u201154","article-title":"SCORE2 risk prediction algorithms:models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"9438","key":"10.1016\/j.diabet.2026.101725_bib0180","first-page":"937\u201152","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0181","doi-asserted-by":"crossref","first-page":"1874\u20112071","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0182","doi-asserted-by":"crossref","first-page":"319\u201125","DOI":"10.1016\/j.amjcard.2007.08.033","article-title":"Impact of systemic hypertension on the cardiovascular benefits of statin therapy\u2013a meta-analysis","volume":"101","author":"Messerli","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0183","first-page":"73\u20119","article-title":"Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice","volume":"108","author":"Agca","year":"2022","journal-title":"Heart Br Card Soc"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0184","doi-asserted-by":"crossref","first-page":"17\u201128","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders","volume":"76","author":"Agca","year":"2017","journal-title":"Rheum Dis"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0185","doi-asserted-by":"crossref","first-page":"480\u20119","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumor necrosis factor inhibitors, non-steroidal anti-inflammatory drugs, and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0186","first-page":"270\u201190","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0187","first-page":"5\u201118","article-title":"Cardiovascular risk assessment in people living with HIV: a systematic review and meta-analysis of real-life data","volume":"18","author":"Grand","year":"2020","journal-title":"Curr HIV Res"},{"issue":"8","key":"10.1016\/j.diabet.2026.101725_bib0188","doi-asserted-by":"crossref","first-page":"687\u201199","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0189","first-page":"99\u2011109","article-title":"Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidemia:a systematic review and meta-analysis","volume":"54","author":"Nirmala","year":"2022","journal-title":"Infect Dis Lond Engl"},{"issue":"9976","key":"10.1016\/j.diabet.2026.101725_bib0191","first-page":"1397\u2011405","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"15","key":"10.1016\/j.diabet.2026.101725_bib0192","doi-asserted-by":"crossref","first-page":"1571\u201182","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.diabet.2026.101725_bib0193","doi-asserted-by":"crossref","first-page":"1489\u201199","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.diabet.2026.101725_bib0194","doi-asserted-by":"crossref","first-page":"1500\u20119","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabet.2026.101725_bib0195","first-page":"337\u201142","article-title":"LDL lowering effect of PCSK9 inhibition is reduced in women","volume":"9","author":"Myasoedova","year":"2023","journal-title":"Heart J Cardiovasc Pharmacother"},{"issue":"34","key":"10.1016\/j.diabet.2026.101725_bib0196","doi-asserted-by":"crossref","first-page":"3213\u201123","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance:a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Heart J"},{"issue":"20","key":"10.1016\/j.diabet.2026.101725_bib0197","doi-asserted-by":"crossref","first-page":"2602\u201118","DOI":"10.1016\/j.jacc.2020.03.060","article-title":"Summary of updated recommendations for primary prevention of cardiovascular disease in women: review","volume":"75","author":"Cho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0198","doi-asserted-by":"crossref","first-page":"133\u201140","DOI":"10.1097\/MOL.0000000000000927","article-title":"Lipid metabolism during pregnancy: consequences for mother and child","volume":"35","author":"Mulder","year":"2024","journal-title":"Opin Lipidol"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0199","doi-asserted-by":"crossref","first-page":"oeae032","DOI":"10.1093\/ehjopen\/oeae032","article-title":"Dyslipidaemia management in pregnant patients: a 2024 update","volume":"4","author":"Lewek","year":"2024","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.diabet.2026.101725_bib0200","first-page":"dgaf409","article-title":"Course of pregnancies and occurrence of acute pancreatitis in women with chylomicronemia","author":"Larouche","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2026.101725_bib0201","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2026.101725_bib0202","article-title":"Pravastatin in preeclampsia:meta-analysis and systematic review","volume":"9","author":"M\u00e9sz\u00e1ros","year":"2022","journal-title":"Front Med"},{"issue":"10\u201111","key":"10.1016\/j.diabet.2026.101725_bib0203","first-page":"651\u20118","article-title":"Progestins and cardiovascular risk markers","volume":"65","author":"Sitruk-Ware","year":"2000","journal-title":"Steroids"},{"issue":"24","key":"10.1016\/j.diabet.2026.101725_bib0204","doi-asserted-by":"crossref","first-page":"2257\u201166","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2026.101725_bib0205","article-title":"Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study","volume":"388","author":"L\u00f8kkegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2026.101725_bib0206","unstructured":"World Health Organizationed. World Health Organization; 2011. 146 p."},{"key":"10.1016\/j.diabet.2026.101725_bib0207","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 [Internet]. [cited Sept. 29, 2025]. Contraception in women at cardiovascular risk. Available at: https:\/\/www.has-sante.fr\/jcms\/c_1638478\/fr\/contraception-chez-la-femme-a-risque-cardiovasculaire."},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0208","doi-asserted-by":"crossref","first-page":"203\u201111","DOI":"10.1038\/s41569-023-00926-7","article-title":"The menopausal transition period and cardiovascular risk","volume":"21","author":"Mehta","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0209","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002229.pub4","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"10.1016\/j.diabet.2026.101725_bib0210","doi-asserted-by":"crossref","first-page":"e506\u201132","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause Transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American heart association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.diabet.2026.101725_bib0211","doi-asserted-by":"crossref","first-page":"597\u2011610","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: whom, what,, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0212","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12877-020-01801-7","article-title":"A scoping review of the clinical frailty scale","volume":"20","author":"Church","year":"2020","journal-title":"BMC Geriatr"},{"issue":"10263","key":"10.1016\/j.diabet.2026.101725_bib0213","first-page":"1644\u201152","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 40\u201370-100: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"22","key":"10.1016\/j.diabet.2026.101725_bib0214","doi-asserted-by":"crossref","first-page":"2090\u20119","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.diabet.2026.101725_bib0215","doi-asserted-by":"crossref","first-page":"1979\u201181","DOI":"10.1161\/CIRCULATIONAHA.117.028271","article-title":"Primary prevention with statin therapy in the elderly: from the contemporary JUPITER and HOPE-3 randomized trials","volume":"135","author":"Ridker","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0216","first-page":"992\u20111003","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75)::randomized trial","volume":"140","author":"Sasaki J","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2026.101725_bib0217","first-page":"k3359","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"52018","journal-title":"BMJ"},{"issue":"10170","key":"10.1016\/j.diabet.2026.101725_bib0218","first-page":"407\u201115","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"10263","key":"10.1016\/j.diabet.2026.101725_bib0219","first-page":"1637\u201143","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"43","key":"10.1016\/j.diabet.2026.101725_bib0220","doi-asserted-by":"crossref","first-page":"3516\u201125","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","author":"Giral","year":"2019","journal-title":"Eur Heart J"},{"issue":"10263","key":"10.1016\/j.diabet.2026.101725_bib0221","first-page":"1637\u201143","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0222","doi-asserted-by":"crossref","first-page":"179\u201185","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.diabet.2026.101725_bib0223","doi-asserted-by":"crossref","first-page":"619\u201127","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"39","key":"10.1016\/j.diabet.2026.101725_bib0224","first-page":"3925\u201146","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis:: a European Atherosclerosis Society consensus statement","volume":"43","author":"Mora S","year":"2022","journal-title":"Heart J"},{"issue":"12","key":"10.1016\/j.diabet.2026.101725_bib0225","doi-asserted-by":"crossref","first-page":"828\u201147","DOI":"10.1016\/j.acvd.2021.10.009","article-title":"Lipoprotein(a):Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci\u00e9t\u00e9 Francophone d\u2019Ath\u00e9roscl\u00e9rose (NSFA)","volume":"114","author":"Durlach","year":"2021","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.diabet.2026.101725_bib0226","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100885","article-title":"Lipoprotein(a) throughout life in women","volume":"20","author":"Corral","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.diabet.2026.101725_bib0227","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels International declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"issue":"10155","key":"10.1016\/j.diabet.2026.101725_bib0228","first-page":"1311\u201120","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events:individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"13","key":"10.1016\/j.diabet.2026.101725_bib0229","doi-asserted-by":"crossref","first-page":"1278\u201188","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145):a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0230","doi-asserted-by":"crossref","first-page":"711\u20115","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin-\/9, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0231","doi-asserted-by":"crossref","first-page":"244\u201155","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabet.2026.101725_bib0232","first-page":"753","article-title":"Lp(a)-lowering agents in development: era in tackling the burden of cardiovascular risk?","volume":"18","author":"Katsiki","year":"2025","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.diabet.2026.101725_bib0233","doi-asserted-by":"crossref","first-page":"1\u20119","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) Lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0234","doi-asserted-by":"crossref","first-page":"97\u2011106","DOI":"10.1016\/j.pcad.2016.08.006","article-title":"Diagnosis and treatment of high density lipoprotein deficiency","volume":"59","author":"Schaefer","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.diabet.2026.101725_bib0235","doi-asserted-by":"crossref","first-page":"157\u201163","DOI":"10.1097\/MOL.0b013e32803dbdd6","article-title":"Genetic factors affecting HDL levels, structure, metabolism, and function","volume":"18","author":"Sviridov","year":"2007","journal-title":"Opin Lipidol"},{"key":"10.1016\/j.diabet.2026.101725_bib0236","unstructured":"2021_06_scientific_argument_genetic_intestinal_hypocholesterolemia_vf.pdf [Internet]. [cited 2025 Sep 29]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/2021_06_argumentaire_scientifique_hypocholesterolemie_intestinale_genetique_vf.pdf."},{"issue":"3","key":"10.1016\/j.diabet.2026.101725_bib0237","doi-asserted-by":"crossref","first-page":"258\u201167","DOI":"10.1001\/jamacardio.2022.5271","article-title":"Association of rare protein-truncating DNA variants in APOB or PCSK9 with low-density lipoprotein cholesterol level and risk of coronary heart disease","volume":"8","author":"Dron","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.diabet.2026.101725_bib0238","first-page":"166","article-title":"Prevalence of liver steatosis and fibrosis in adults with primary hypobetaliproteinemia: results from the HYPOCHOL study","volume":"23","author":"Smati","year":"2025","journal-title":"Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"4S","key":"10.1016\/j.diabet.2026.101725_bib0239","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"38","key":"10.1016\/j.diabet.2026.101725_bib0240","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:19:40Z","timestamp":1777288780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":238,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1262363626000042"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101725","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Atherosclerosis Society (NSFA) and the French Society of Cardiology (SFC)","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.102471","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101725"}}